You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):目前雙價HPV疫苗已完成全國主要省份的准入,將為今年的業績持續貢獻增量
格隆匯 04-12 21:53

格隆匯4月12日丨沃森生物(300142.SZ)於2023年4月12日15:00-17:00召開2022年度業績説明會,就“公司對2023年的發展有哪幾點信心。”,公司表示,2023年,公司將繼續提升13價肺炎結合疫苗的市場滲透率和佔有率;今年也是公司雙價HPV疫苗上市後的第一個完整銷售年,目前雙價HPV疫苗已完成全國主要省份的准入,將為公司今年的業績持續貢獻增量。同時,公司將繼續加強其他產品如23價肺炎多糖疫苗等的銷售,預計產銷量都將會持續提升,具體以公司後續披露的信息為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account